At OCT DACH 2025, industry members noted that the implementation of AI in clinical trials must be carefully thought out.

Gene anticipates filing a biologics licence application (BLA) for detalimogene voraplasmid to the FDA in H2 2026.

If Roche's fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.

Despite the trial failure, Sarepta will still seek full approval of AMONDYS 45 and VYONDYS 53 in DMD from the FDA.

At the European Society for Medical Oncology (ESMO) 2025 event, held in Berlin, Germany, between 17-21 October, Celcuity ...

While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...

Alkermes announced that the drug met its dual primary endpoints, however this was only in the two high dose cohorts and the data was “adjusted for multiplicity”. Image credit: MediaNews Group / Boston ...

Eli Lilly will advance eloralintide to Phase III trials in obesity. Image credit: Michael Vi / Shutterstock.com Eli Lilly is advancing its obesity treatment candidate, which is an alternative to ...

If approved in AFRS, it would become the ninth US approved indication for Dupixent. Image credit: Angelina Avei / Shutterstock.com Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ...

Novo Nordisk said that the data suggests that the benefits of Wegovy go further than just weight loss in the patient population. Image credit: PJ McDonnell / Shutterstock.com. Novo Nordisk’s oral ...

Centessa is advancing ORX750 to pivotal trials based on the Phase IIa data. Image credit: SOPA Images /LightRocket via Getty Images Centessa Pharmaceuticals executives will be breathing a sigh of ...